MEETING INFORMATION: See the Utah Public Notice Website. Search Categories: Government: State Entity: Department of Health Body: Cannabinoid Product Board.

Cannabinoid Product Board Information

The Cannabinoid Product Board (CPB) is the result of the Cannabinoid Research Act, (H.B. 130) that was passed and was signed into law during the 2017 Utah General Legislative Session. During the 2018 Utah General Legislative Session, amendments (H.B. 25) were made to Cannabinoid Research Act as follows:

  1. The composition of the CPB was modified from three board members being members of the Controlled Substance Advisory Committee to one; and
  2. The duties of the CPB were broadened to include review of research regarding “expanded cannabinoid products” which includes cannabinoid products with significant tetrahydrocannabinol (THC) content.

The Cannabinoid Research Act directs the Utah Department of Health (UDOH) to form and facilitate the CPB. As stated in the legislation, the purpose of the CPB is to review available research related to the human use of cannabinoid products. Specifically, the CPB evaluates the safety and efficacy of cannabinoid products and expanded cannabinoid products in terms of: 1) medical conditions that respond to cannabinoid products; 2) dosage amounts and their medical forms; and 3) interactions between cannabinoid products, expanded cannabinoid products, and other treatments. The CPB may only review research that has been approved by an Institutional Review Board, or approved/conducted by the federal government.

From this research, the CPB is directed to develop prescribing guidelines that may potentially be used by qualified medical providers recommending cannabinoid products to their patients. The CPB is directed to report the findings of their evaluation in writing to the Health and Human Services Interim Committee before November 1st of each year.

BOARD MEMBERS

Perry G. Fine, M.D. (Board Chair)

Professor of Anesthesiology, Division of Pain Medicine, School of Medicine, University of Utah

Michael J. Crookston, M.D., F.A.P.A., F.A.S.A.M.

Medical Director, Adult Dayspring

Ed Redd, M.D.

Internal Medicine Physician

Past member of the Utah State Legislature

Karen S. Wilcox, Ph.D.

Professor and Chair, Department of Pharmacology and Toxicology, University of Utah

Laboratory of Glial/Neuronal Interactions in Epilepsy

Katherine Carlson, M.D., M.S.

Addiction Psychiatrist

Medical Director, Project Reality Substance Abuse Treatment and Prevention Services

Lauren J. Heath, Pharm.D., M.S., B.C.A.C.P.

Assistant Professor (Clinical), Department of Pharmacotherapy, University of Utah College of Pharmacy

Brian Keith Zehnder, M.D.

Medical Director, Exodus Healthcare Network, PLLC,

Past member of the Utah State Legislature

AGENDAS MINUTES RECORDINGS

October 27, 2020 | PDF

October 27, 2020 | PDF

CPB Youtube Channel

October 13, 2020 | PDF

October 13, 2020 | PDF

CPB Youtube Channel

September 22, 2020 | PDF

September 22, 2020 | PDF

CPB Youtube Channel

August 11, 2020 | PDF

August 11, 2020 | PDF

Google Site

June 9, 2020 | PDF

June 9, 2020 | PDF

Google Site

April 14, 2020 | PDF

April 14, 2020 | PDF

Google Site

February 11, 2020 | PDF

February 11, 2020 | PDF

Google Site

January 14, 2020 | PDF

January 14, 2020 | PDF

Google Site

CPB Research By Diagnosis

Condition/Subject

Approved Condition

CPB Discussion Notes

CPB Guidance Document

Presentations & Relevant Documents

General Use

N/A

PDF

Chronic Pain

Yes

A presentation was given by Dr. Perry Fine, M.D., during the Aug 2020 meeting. Notes from the CPB’s discussion can be found in the 2020 Meeting Minutes document and also in the 2020 Annual Report.

PDF

ALS

Yes

PDF

Alzheimer’s 

Yes

PDF

HIV/AIDS

Yes

PDF

Multiple Sclerosis

Yes

A presentation was given by Dr. Joel Ehrenkranz, M.D., during the June 2020 CPB meeting. Notes from the CPB’s discussion can be found in the 2020 Meeting Minutes document and also in the 2020 Annual Report.

PDF

Autism

Yes

PDF

Cancer

Yes

PDF

Cancer and Chemotherapy-Induced Nausea and Vomiting

Yes

PDF

Crohn’s Disease and Ulcerative Colitis

Yes

PDF

Epilepsy

Yes

PDF

PTSD

Yes

A presentation by Dr. Katherine Carlson was given during the December 2020 meeting. Notes from the CPB’s discussion can be found in the 2021 Meeting Minutes document and also in the 2021 Annual Report.

PDF

Cannabis and Cannabinoids for Post Traumatic Stress Disorder

Anxiety

No

A presentation by Dr. Michael Crookston was given during the December 2020 meeting. Notes from the CPB’s discussion can be found in the 2021 Meeting Minutes document and also in the 2021 Annual Report.

N/A

Anxiety Whereas Statements

Opioid Use/Opioid Use Disorder

No

A presentation by Dr. Adam Gordon, MD MPH FACP DFASAM, was given during the January 2021 CPB meeting. Notes from the CPB’s discussion can be found in the 2021 Meeting Minutes document and also in the 2021 Annual Report. 

N/A

OUD Document (coming soon)